EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast

Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalKorean Journal of Pathology
Volume47
Issue number2
DOIs
Publication statusPublished - 2013 Jun 26

Fingerprint

Carcinoma, Ductal, Breast
erbB-1 Genes
Gene Amplification
Epidermal Growth Factor Receptor
Proteins
Keratin-6
Keratin-5
Breast Neoplasms
Fluorescence In Situ Hybridization
Neoplasms
Disease-Free Survival
Therapeutics
Biomarkers

Keywords

  • Breast neoplasms
  • Epidermal growth factor
  • Gene amplification
  • Protein expression
  • Receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast. / Hwangbo, Won; Lee, Jeong Hyeon; Ahn, Sangjeong; Kim, Seojin; Park, Kyong Hwa; Kim, Chul Hwan; Kim, Insun.

In: Korean Journal of Pathology, Vol. 47, No. 2, 26.06.2013, p. 107-115.

Research output: Contribution to journalArticle

Hwangbo, Won ; Lee, Jeong Hyeon ; Ahn, Sangjeong ; Kim, Seojin ; Park, Kyong Hwa ; Kim, Chul Hwan ; Kim, Insun. / EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast. In: Korean Journal of Pathology. 2013 ; Vol. 47, No. 2. pp. 107-115.
@article{92538b6cf40a4bd19783f7114bfb94fa,
title = "EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast",
abstract = "Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1{\%}); 5.9{\%} were of luminal type, 25.3{\%} of epidermal growth factor receptor 2 (HER-2) type, and 79.3{\%} of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0{\%}); 41.2{\%} of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2{\%} of the HER-2-, EGFR+, CK5/6- group, and 19.1{\%} of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3{\%} of the EGFR protein 1+ expression cases, 15.9{\%} of 2+ expression cases, and 38.5{\%} of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60{\%}), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.",
keywords = "Breast neoplasms, Epidermal growth factor, Gene amplification, Protein expression, Receptor",
author = "Won Hwangbo and Lee, {Jeong Hyeon} and Sangjeong Ahn and Seojin Kim and Park, {Kyong Hwa} and Kim, {Chul Hwan} and Insun Kim",
year = "2013",
month = "6",
day = "26",
doi = "10.4132/KoreanJPathol.2013.47.2.107",
language = "English",
volume = "47",
pages = "107--115",
journal = "Journal of Pathology and Translational Medicine",
issn = "2383-7837",
publisher = "Korean Society of Pathologists",
number = "2",

}

TY - JOUR

T1 - EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast

AU - Hwangbo, Won

AU - Lee, Jeong Hyeon

AU - Ahn, Sangjeong

AU - Kim, Seojin

AU - Park, Kyong Hwa

AU - Kim, Chul Hwan

AU - Kim, Insun

PY - 2013/6/26

Y1 - 2013/6/26

N2 - Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

AB - Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki- 67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

KW - Breast neoplasms

KW - Epidermal growth factor

KW - Gene amplification

KW - Protein expression

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=84879207204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879207204&partnerID=8YFLogxK

U2 - 10.4132/KoreanJPathol.2013.47.2.107

DO - 10.4132/KoreanJPathol.2013.47.2.107

M3 - Article

VL - 47

SP - 107

EP - 115

JO - Journal of Pathology and Translational Medicine

JF - Journal of Pathology and Translational Medicine

SN - 2383-7837

IS - 2

ER -